Addendum – European Economic Area Jurisdictions
An offer made under the PSU Program is made to align the interests of the Participant with the interests of the Company’s shareholders, to incentivize and share the continued success of the Company, and to retain employees contributing to the long-term success of the Company.
The PSUs are offered by the Company. The shares which are the subject of the PSUs are ADSs. More information in relation to the Company, including the share price, can be found at the following web address: https://investors.ascendispharma.com/.
The details of the offer are set out within the documents listed at clause 2.1 above. The number of ADSs that are the subject of an offer to the Participant will be set out in the Grant Acceptance document issued to them.
The obligation to publish a prospectus does not apply to an offer made in Belgium, Denmark, Germany, Italy, Luxembourg, Netherlands, Norway, Spain or Sweden because of the employee offer exemption set out at Article 1(4)(i) of the EU Prospectus Regulation (together with any applicable local implementing legislation).
The obligation to publish a prospectus does not apply to an offer made in France because the PSUs are considered to be non-transferable securities and so will fall outside of the scope of the EU Prospectus Regulation (together with any applicable local implementing legislation).
The obligation to publish a prospectus does not apply to an offer made in Finland because the ADSs underlying the PSUs are offered for no consideration and so will fall outside of the scope of the EU Prospectus Regulation (together with any applicable local implementing legislation).
The obligation to publish a prospectus does not apply to an offer made in Portugal because of the ‘fewer than 150 persons’ exemption set out at Article 1(4)(b) of the EU Prospectus Regulation (together with any applicable local implementing legislation).